IDBS and Alchemi partnered to accelerate AI-driven regulatory filings by connecting AI agents to IDBS Polar’s governed data foundation across the drug development lifecycle. The collaboration targets chronic bottlenecks in CMC documentation, where teams often spend months assembling data, reconstructing process histories, and drafting submission reports. IDBS said Polar keeps traceable, auditable data at the point of creation, addressing compliance gaps when AI tools pull information from outside validated systems. Alchemi’s agents are intended to draft regulatory documents faster while keeping a human-in-the-loop workflow for review and sign-off. The companies claim that teams in Alchemi deployments have produced certain reports up to 70% faster while preserving compliance trails. For regulated biotech operations, the partnership emphasizes that “agentic” AI adoption is moving toward audit-ready workflows rather than standalone drafting tools.